The company’s recently acquired JAS Diagnostic unit is the distributor for the Liasys analyzer in the US and supplier of the associated chemistry reagents. JAS prepared and submitted the 501(k) application on behalf of the manufacturer, Analyzer Medical System, headquartered in Rome, Italy.
Liasys is said to be a fully automatic random access, continuous loading, easy access bench top clinical chemistry and immunoturbidimetric analyzer. The instrument features primary tubes sampling, capacitive liquid level sensing, positive identification of the samples, and module for ion selective electrode.
According to the company, the Liasys analyzer is suitable to perform the daily routine of low/medium-sized laboratories in an entirely safe and reliable way, providing flexible and cost effective solutions. The Liasys multitasking and user-friendly software also enhances the system’s potential and performance.
Richard DePiano, Sr, chairman and CEO of Escalon, said: “We are pleased to announce this FDA clearance, which not only illustrates the strategic value of our recent acquisition of JAS Diagnostic but also our ability to expand our position in the clinical chemistry market.”